23andMe Target of Unusually Large Options Trading (NASDAQ:ME)

Posted by Defense World Staff on Mar 26th, 2025

23andMe Holding Co. (NASDAQ:ME – Get Free Report) was the target of unusually large options trading activity on Tuesday. Investors bought 2,416 put options on the company. This is an increase of approximately 139% compared to the typical daily volume of 1,009 put options.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 23andMe in a research note on Saturday.

View Our Latest Report on ME

Institutional Investors Weigh In On 23andMe

Hedge funds have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC bought a new position in shares of 23andMe during the fourth quarter worth approximately $26,000. Leavell Investment Management Inc. bought a new position in 23andMe during the 4th quarter worth $32,000. MassMutual Private Wealth & Trust FSB acquired a new stake in shares of 23andMe during the fourth quarter worth $40,000. Virtu Financial LLC bought a new stake in shares of 23andMe in the fourth quarter valued at about $49,000. Finally, Shay Capital LLC grew its stake in shares of 23andMe by 71.7% in the fourth quarter. Shay Capital LLC now owns 702,530 shares of the company’s stock valued at $2,283,000 after acquiring an additional 293,358 shares in the last quarter. Institutional investors and hedge funds own 36.10% of the company’s stock.

23andMe Stock Down 11.0 %

Shares of 23andMe stock opened at $0.65 on Wednesday. 23andMe has a 12-month low of $0.61 and a 12-month high of $12.76. The business’s 50 day moving average is $2.44 and its 200-day moving average is $3.85. The stock has a market cap of $17.44 million, a P/E ratio of -0.04 and a beta of 1.19.

23andMe (NASDAQ:ME – Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

23andMe Company Profile

(Get Free Report)

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.